- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Top Stock Picks from Analysts
Swiss Pharmaceuticals & Biotech Top Stock Picks from Analysts
Results
11
Companies which are more than 50% undervalued based on analyst price target.
11 companies
Bachem Holding
Market Cap: CHF 3.7b
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
BANB
CHF 48.72
7D
-5.7%
1Y
-27.4%
Siegfried Holding
Market Cap: CHF 3.0b
Engages in contract development and manufacturing of active pharmaceutical ingredient (API) and finished dosage forms worldwide.
SFZN
CHF 69.30
7D
-9.5%
1Y
-37.3%
Tecan Group
Market Cap: CHF 1.7b
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally.
TECN
CHF 133.60
7D
-3.6%
1Y
-35.8%
SKAN Group
Market Cap: CHF 1.0b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 46.30
7D
-6.9%
1Y
-34.6%
PolyPeptide Group
Market Cap: CHF 724.2m
Operates as a contract development and manufacturing company in Europe, the United States, and India.
PPGN
CHF 21.95
7D
-8.7%
1Y
-16.5%
Basilea Pharmaceutica
Market Cap: CHF 576.9m
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
BSLN
CHF 46.95
7D
1.8%
1Y
18.1%
Santhera Pharmaceuticals Holding
Market Cap: CHF 137.4m
A specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia.
SANN
CHF 10.28
7D
-3.7%
1Y
23.9%
BioVersys
Market Cap: CHF 129.8m
A clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria.
BIOV
CHF 22.20
7D
-19.3%
1Y
n/a
Molecular Partners
Market Cap: CHF 123.6m
A clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland.
MOLN
CHF 3.31
7D
6.6%
1Y
-32.6%
Curatis Holding
Market Cap: CHF 60.9m
Engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
CURN
CHF 12.20
7D
-2.8%
1Y
-22.8%
Addex Therapeutics
Market Cap: CHF 8.3m
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
ADXN
CHF 0.057
7D
-7.8%
1Y
-3.1%